Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.43 |
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 2/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20787749 | 1.00 | PTGS1 (0.67) | PTGS1GSTK1MAPTPTGS2KDM4E | |
| SCHEMBL20787756 | 0.89 | PTGS1 (0.67) | PTGS1GSTK1GLO1FOLH1NOD1 | |
| SCHEMBL6665444 | 0.89 | PTGS1 (0.67) | PTGS1GSTK1MAPTPTGS2GLO1 | |
| SCHEMBL2928611 | 0.89 | PTGS1 (0.67) | PTGS1GSTK1GLO1FOLH1NOD1 | |
| Glutathione SCHEMBL237150 | 0.89 | PTGS1 (0.83) | PTGS1GSTK1MAPTPTGS2KDM4E | |
| Glutathione SCHEMBL5131162 | 0.89 | PTGS1 (0.83) | PTGS1GSTK1MAPTPTGS2KDM4E | |
| Glutathione SCHEMBL237151 | 0.89 | PTGS1 (0.83) | PTGS1GSTK1MAPTPTGS2KDM4E | |
| Glutathione SCHEMBL19612768 | 0.89 | PTGS1 (0.83) | PTGS1GSTK1MAPTPTGS2KDM4E | |
| SCHEMBL28502763 | 0.88 | PTGS1 (0.69) | PTGS1GSTK1MAPTPTGS2KDM4E | |
| SCHEMBL23161509 | 0.88 | PTGS1 (0.69) | PTGS1GSTK1MAPTPTGS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350436-A | Method for synthesizing acetyl glutathione by biological enzyme method | 上海克琴科技有限公司 | 2025-01-24 | — | — | CN | claimed |
| EP-3270889-B1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2024-02-07 | — | — | EP | claimed |
| US-11547757-B2 | Elimination of exotic pathogens | Healing Oil Extracts, LLC. (US) | 2023-01-10 | — | — | US | claimed |
| WO-2022074181-A1 | NANOCARRIER FORMULATIONS FOR INHALATION | EnhanX Biopharm Inc. (TW) | 2022-04-14 | — | — | WO | claimed |
| EP-3395372-B1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | ENHANX BIOPHARM INC (TW) | 2022-04-06 | — | — | EP | claimed |
| EP-1240902-B1 | CARBONYL STRESS-AMELIORATING AGENTS | KUROKAWA KIYOSHI (JP) | 2013-02-13 | — | — | EP | claimed |
| US-20110245188-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR CONDITIONS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-06 | — | — | US | claimed |
| US-20110160305-A1 | Oral Delivery of Therapeutic Doses of Glutathione | AGB INNOVATIONS, LLC | 2011-06-30 | — | — | US | claimed |
| US-20100247463-A1 | N-(PHOSPHONOALKYL)-AMINO ACIDS, DERIVATIVES THEREOF AND COMPOSITIONS AND METHODS OF USE | YU RUEY J | 2010-09-30 | — | — | US | claimed |
| US-7776844-B2 | N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use | YU RUEY J | 2010-08-17 | — | — | US | claimed |
| WO-2004012652-A9 | TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI OXIDANT COMPOUNDS | YISSUM RES DEV CO (IL) | 2004-06-17 | — | — | WO | claimed |
| WO-2004012652-A2 | TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI OXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-02-12 | — | — | WO | claimed |
| WO-2004010968-A1 | NON-AMPHOTERIC GLUTATHIONE DERIVATIVE COMPOSITIONS FOR TOPICAL APPLICATION | YU RUEY J (US) | 2004-02-05 | — | — | WO | claimed |
| EP-1242070-A4 | TREATMENT OF ISCHEMIC BRAIN INJURIES WITH BRAIN TARGETTED ANTIOXIDANT COMPOUNDS | YISSUM RES DEV CO (IL) | 2003-05-28 | — | — | EP | claimed |
| US-20030083266-A1 | Treatment of ischemic brain injuries with brain targeted antioxidant compounds | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-05-01 | — | — | US | claimed |
| EP-1242070-A2 | TREATMENT OF ISCHEMIC BRAIN INJURIES WITH BRAIN TARGETTED ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-09-25 | — | — | EP | claimed |
| US-6369106-B1 | SULFHYDRYL CONTAINING COMPOUND AS ANTIOXIDANT | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-04-09 | — | — | US | claimed |
| WO-2001047469-A2 | TREATMENT OF ISCHEMIC BRAIN INJURIES WITH BRAIN TARGETTED ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-07-05 | — | — | WO | claimed |
| EP-0948258-A1 | BRAIN TARGETED LOW MOLECULAR WEIGHT HYDROPHOBIC ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-10-13 | — | — | EP | claimed |
| WO-1998029375-A1 | BRAIN TARGETED LOW MOLECULAR WEIGHT HYDROPHOBIC ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1998-07-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245188-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR CONDITIONS | HMGCR, GCKR, GSR | PTGS1 173/4885GSTK1 15/4885MAPT 2508/4885 |
| US-20030083266-A1 | Treatment of ischemic brain injuries with brain targeted antioxidant compounds | GPX4, GPX1, TXN2 | PTGS1 192/4885GSTK1 13/4885MAPT 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.